Organoid 3D Culture
iPSC- and Patient-Derived Organoids for Drug Testing and Disease Modeling
At PharmaPlanter Technologies, using our proprietary reprogramming and differentiation protocols, we are developing a series of iPSC- and patient-derived organoid models that mimic human physiology and disease pathology with high fidelity. These models are currently being deployed for drug testing, disease modeling, toxicity assessment, and functional genomics across multiple therapeutic areas. Our organoid systems have demonstrated robust utility in capturing patient-specific phenotypes, enabling more accurate prediction of drug responses and toxicities compared to conventional cell lines or animal models. These organoids serve as the foundation for patient-specific in vitro models that capture the genetic and phenotypic complexity of human diseases. This allows us to study disease progression, evaluate target biology, and assess the therapeutic potential of candidate drugs in a physiologically relevant context. We are currently applying these models to evaluate compounds for hepatotoxicity, cardiotoxicity, and neurotoxicity, leveraging standardized protocols for functional assays including electrophysiological measurements, metabolic profiling, and stress response analyses.
Our platform offers a scalable and reproducible system to bridge the gap between preclinical models and clinical relevance. This platform is central to our commitment to improving drug development efficiency, reducing reliance on animal testing, and advancing the frontiers of personalized medicine.
iPSC-Derived Organoids
Tumour-Derived Organoids
Request a Quote:
Interested in working together? Fill out some info and we will be in touch shortly! We can't wait to hear from you!